open access

Vol 9, No 2 (2014)
Review Papers
Published online: 2014-06-26
Get Citation

Nebivolol from a cardiologist’s and hypertensiologist’s point of view

Beata Wożakowska-Kapłon, Iwona Gorczyca-Michta
Folia Cardiologica 2014;9(2):165-172.

open access

Vol 9, No 2 (2014)
Review Papers
Published online: 2014-06-26

Abstract

Nebivolol is a third-generation beta-blocker with vasodilator properties. Nebivolol is the most beta1-selective blocker available, with a relative affinity for beta1/beta2 receptors > 300. Nebivolol possesses a direct stimulatory effect on endothelial nitric oxide synthase, which results in increased levels of local nitric oxide. In addition, there is evidencethat nebivolol exerts an antioxidant effect, which might produce additional vasodilatory actions. Differences from otherbeta-blockers might include improvement of endothelial function, enhancement of forward flow in arteries, maintenance of exercise tolerance, and overall improved tolerability. Nebivolol has been shown to be a clinically effective beta-blocker when used as initial or add-on therapy for hypertension, as an antianginal agent, or as therapy for patients with heart failure.

Abstract

Nebivolol is a third-generation beta-blocker with vasodilator properties. Nebivolol is the most beta1-selective blocker available, with a relative affinity for beta1/beta2 receptors > 300. Nebivolol possesses a direct stimulatory effect on endothelial nitric oxide synthase, which results in increased levels of local nitric oxide. In addition, there is evidencethat nebivolol exerts an antioxidant effect, which might produce additional vasodilatory actions. Differences from otherbeta-blockers might include improvement of endothelial function, enhancement of forward flow in arteries, maintenance of exercise tolerance, and overall improved tolerability. Nebivolol has been shown to be a clinically effective beta-blocker when used as initial or add-on therapy for hypertension, as an antianginal agent, or as therapy for patients with heart failure.

Get Citation

Keywords

nebivolol, hypertension, heart failure

About this article
Title

Nebivolol from a cardiologist’s and hypertensiologist’s point of view

Journal

Folia Cardiologica

Issue

Vol 9, No 2 (2014)

Pages

165-172

Published online

2014-06-26

Bibliographic record

Folia Cardiologica 2014;9(2):165-172.

Keywords

nebivolol
hypertension
heart failure

Authors

Beata Wożakowska-Kapłon
Iwona Gorczyca-Michta

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

 

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl